Literature DB >> 11924533

Effects of low doses of inhaled nitric oxide combined with oxygen for the evaluation of pulmonary vascular reactivity in patients with pulmonary hypertension.

E Azeka1, J O Costa Auler, L Kajita, A C Alliman, J A A Franchini Ramires, M Ebaid.   

Abstract

The purpose of this study was to evaluate the hemodynamic effects of inhaled nitric oxide in oxygen (NO + O2) in patients with pulmonary hypertension. Eighteen patients (median age 31.5 months) with pulmonary hypertension inhaled through a mask 100% O2 and 20 parts per million NO + inspired O2 fraction (FiO2) at 0.4. Hemodynamic measurements were made at baseline and after O2 and NO + O2 administration. The pulmonary vascular resistance index decreased after inhalation of O2 and NO + O2 (p = 0.0018 and p = 0.0003, respectively), the decrease being significantly greater after NO + O2 (p = 0.0311). Concerning the transpulmonary pressure gradient, a reduction occurred in values after O2 and NO + O2 inhalation when compared with baseline values (p = 0.0014 and p = 0.0008). In patients with congenital heart disease, an increase occurred in pulmonary blood flow after O2 (p = 0.0089) and NO + O2 (p = 0.0019) compared with baseline values, and an increase also occurred in the pulmonary/systemic blood flow ratio after NO + O2 (p = 0.0017). The main side effect related to NO + O2 was pulmonary congestion in 3 patients. Low doses of NO combined with O2 demonstrated a selective pulmonary vasodilator response in patients with pulmonary hypertension. Despite its use for testing pulmonary reactivity, inhalation of NO + O2 should be carefully administered because of the potential risk of pulmonary congestion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11924533     DOI: 10.1007/s00246-001-0006-2

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  7 in total

1.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells.

Authors:  Weiling Xu; Thomas Koeck; Abigail R Lara; Donald Neumann; Frank P DiFilippo; Michelle Koo; Allison J Janocha; Fares A Masri; Alejandro C Arroliga; Constance Jennings; Raed A Dweik; Rubin M Tuder; Dennis J Stuehr; Serpil C Erzurum
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

2.  Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension.

Authors:  Fares A Masri; Suzy A A Comhair; Iva Dostanic-Larson; Francisco Takao Kaneko; Raed A Dweik; Alejandro C Arroliga; Serpil C Erzurum
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

3.  Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response.

Authors:  B C Cannon; T F Feltes; J Kennard Fraley; R G Grifka; E M Riddle; J P Kovalchin
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

4.  Simplified pulmonary vasodilatory testing in the cardiac catheterization laboratory with nasal cannula nitric oxide.

Authors:  M Scheurer; V Bandisode; A M Atz
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

5.  Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension.

Authors:  Gholam Hossein Ajami; Mohammad Borzoee; Mohammad Radvar; Hamid Amoozgar
Journal:  Pediatr Cardiol       Date:  2007-12-04       Impact factor: 1.655

Review 6.  Clinical recommendations for postoperative care after heart transplantation in children: 21 years of a single-center experience.

Authors:  Estela Azeka; Marcelo Biscegli Jatene; Ana Cristina Tanaka; Filomena Regina Galas; Ludhmilla Abrahao Hajjar; Nana Miura; Jose Otavio Costa Auler Junior
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

Review 7.  Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Pulmonary Arterial Hypertension.

Authors:  Feng Zhang; Aidong Chen; Yan Pan; Xingxing Wang; Yu Xu; Ankit A Desai; Haiyang Tang; Ying Han
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-04       Impact factor: 3.947

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.